Euronext has concluded its Extraordinary General Meeting (EGM) today, which saw a number of issues discussed, including the appointment of Stéphane Boujnah as a member of the Managing Board.
Back in September, Euronext announced that Mr. Boujnah would be joining the exchange as its Chief Executive. He joins Euronext from Santander Global Banking and Markets having served previously as its Head of France & Benelux, dating back to 2010 – more recently, he held the role of Head of Continental Europe since mid 2014. He has garnered extensive experience across a plethora of financial markets, namely in European corporates.
A resolution to appoint Stéphane Boujnah as a member of the Managing Board was unanimously approved by shareholders – Mr. Boujnah will commence his role on November 16, 2015 pending the requisite regulatory approvals.
How Will Zero-Fee Investment Platforms Impact Traditional Stock Brokers?Go to article >>
According to Rijnhard van Tets, Chairman of the Supervisory Board of Euronext NV, in a recent statement on the appointment during the EGM: “We are delighted that our shareholders overwhelmingly supported the Supervisory Board’s choice.”
“We remain of the view that Stéphane’s international background and energetic ambition make him the best candidate to take Euronext to the next level and to advance Euronext’s well defined strategy. We are looking forward to working with Stéphane and his team in the coming years. We would also like to thank Jos Dijsselhof and the entire executive team for keeping the ship on its steady course over the last seven months,” he added.
Earlier this week, Euronext made headlines after it launched AtomX, a new service that caters to investors looking to bilaterally negotiate trades. AtomX allows users to fully customize and trade both options and futures, each of which will be cleared through LCH Clearnet, constituting the same clearing pool as the rest of Euronext derivatives positions. The launch comes amidst a push for more compliance and transparency in the clearing of over-the-counter (OTC) derivatives, notwithstanding the systematic risk associated with these instruments.